We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs.
- Authors
Light, Donald W.; Lexehin, Joel; Darrow, Jonathan J.
- Abstract
Over the past 85 years, patients have suffered from a largely hidden epidemic of side effects from drugs that usually have few offsetting benefits. The pharmaceutical industry has corrupted the practice of medicine through its influence over what drugs are developed, how they are tested, and how medical knowledge is created. Since 1906, heavy commercial influence has compromised congressional legislation to protect the public from unsafe drugs. The authorization of user fees in 1992 has turned drug companies into the FDA's prime clients, deepening the regulatory and cultural capture of the agency. Industry has demanded shorter average review times and, with less time to thoroughly review evidence, increased hospitalizations and deaths have resulted. Meeting the needs of the drug companies has taken priority over meeting the needs of patients. Unless this corruption of regulatory intent is reversed, the situation will continue to deteriorate. We offer practical suggestions including: separating the funding of clinical trials from their conduct, analysis, and publication; independent FDA leadership; full public funding for all FDA activities; measures to discourage R&D on drugs with few, if any, new clinical benefits; and the creation of a National Drug Satiety Board.
- Subjects
UNITED States; FRANCE; PHARMACEUTICAL industry; MEDICATION safety; CORRUPTION -- Social aspects; DRUG development; UNITED States. Food &; Drug Administration; HOSPITAL care; CLINICAL trials; GOVERNMENT agencies; ECONOMICS; CORRUPTION; GOVERNMENT agency rules &; practices; CLINICAL trials &; ethics; DRUGS &; economics; DRUG laws; PHARMACOEPIDEMIOLOGY; DRUG control; ORGANIZATIONS &; ethics; CLINICAL medicine; DRUG adulteration; DRUGS; LOBBYING; MARKETING; EVALUATION of medical care; ORGANIZATIONAL behavior; PATENTS; DRUG approval; OFF-label use (Drugs); INVESTIGATIONAL drugs; ETHICS
- Publication
Journal of Law, Medicine & Ethics, 2013, Vol 41, Issue 3, p590
- ISSN
1073-1105
- Publication type
Article
- DOI
10.1111/jlme.12068